/IMNN
IMNN Stock - Imunon, Inc.
Healthcare|BiotechnologyNASDAQ
$3.75-1.06%
$0.04 (-1.06%) • Dec 19
43
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.43
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $4.13
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for IMNN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$3.71 – $3.79
TARGET (TP)$4.31
STOP LOSS$3.45
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.93
52W High$41.22
52W Low$3.56
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | $500,000 | $500,000 | $500,000 |
| Gross Profit | N/A | N/A | $500,000 | $500,000 | $500,000 |
| Gross Margin | N/A | N/A | 100.0% | 100.0% | 100.0% |
| Operating Income | $-19,132,446 | $-21,030,430 | $-24,921,565 | $-21,007,190 | $-18,486,412 |
| Net Income | $-18,620,242 | $-19,514,977 | $-35,898,234 | $-20,769,250 | $-21,483,561 |
| Net Margin | N/A | N/A | -7179.6% | -4153.9% | -4296.7% |
| EPS | $-21.10 | $-28.14 | $-65.55 | $-748.77 | $-131.51 |
Company Overview
Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
IMNNBeat Rate
83%
Last 18 quarters
Avg Surprise
-4.3%
EPS vs Estimate
Beats / Misses
15/3
Last 12 quarters
Latest EPS
$-1.16
Q4 2025
EPS Surprise History
Q1 24
+11.9%
$-0.52vs$-0.59
Q2 24
+8.8%
$-0.52vs$-0.57
Q3 24
+7.3%
$-0.51vs$-0.55
Q4 24
+8.1%
$-0.34vs$-0.37
Q1 25
+36.1%
$-0.23vs$-0.36
Q2 25
+20.0%
$-3.65vs$-4.56
Q3 25
+39.5%
$-1.87vs$-3.09
Q4 25
+32.9%
$-1.16vs$-1.73
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $-1.76 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-1.73 | $-1.16 | +32.9% | ✓ BEAT |
Q3 2025 | Aug 5, 2025 | $-3.09 | $-1.87 | +39.5% | ✓ BEAT |
Q2 2025 | May 12, 2025 | $-4.56 | $-3.65 | +20.0% | ✓ BEAT |
Q1 2025 | Feb 27, 2025 | $-0.36 | $-0.23 | +36.1% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.37 | $-0.34 | +8.1% | ✓ BEAT |
Q3 2024 | Aug 14, 2024 | $-0.55 | $-0.51 | +7.3% | ✓ BEAT |
Q2 2024 | May 13, 2024 | $-0.57 | $-0.52 | +8.8% | ✓ BEAT |
Q1 2024 | Mar 28, 2024 | $-0.59 | $-0.52 | +11.9% | ✓ BEAT |
Q4 2023 | Nov 14, 2023 | $-0.66 | $-0.37 | +43.9% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.71 | $-0.61 | +14.1% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.69 | $-0.68 | +1.4% | ✓ BEAT |
Q1 2023 | Mar 30, 2023 | $-0.80 | $-0.64 | +20.0% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-0.81 | $-0.87 | -7.4% | ✗ MISS |
Q3 2022 | Aug 15, 2022 | $-1.12 | $-0.87 | +22.3% | ✓ BEAT |
Q2 2022 | May 16, 2022 | $-0.99 | $-1.82 | -83.8% | ✗ MISS |
Q1 2022 | Mar 31, 2022 | $-0.90 | $-3.62 | -302.2% | ✗ MISS |
Q4 2021 | Nov 15, 2021 | $-1.20 | $-0.90 | +25.0% | ✓ BEAT |
Q3 2021 | Aug 12, 2021 | $-1.20 | $-0.90 | +25.0% | ✓ BEAT |
Latest News
Imunon Q3 EPS $(1.16) Beats $(1.80) Estimate
📈 PositiveBenzinga•Nov 13, 2025, 12:46 PM
IMUNON Updates on Final Phase 3 Trial for its DNA-Based Ovarian Cancer Therapy
➖ NeutralBenzinga•Nov 10, 2025, 12:44 PM
IMUNON To Present Data From Its Phase 3 OVATION 3 Trial And Phase 2 Minimal Residual Disease Trial On Nov. 10 At R&D Day
📈 PositiveBenzinga•Nov 4, 2025, 01:13 PM
IMUNON To Present Ongoing Phase 3 OVATION 3 Clinical Trial Of IMNN-001 At IGCS 2025 Annual Global Meeting
➖ NeutralBenzinga•Oct 30, 2025, 12:07 PM
IMUNON To Present New Translational Data From Phase 2 OVATION 2 Clinical Trial Of IMNN-001, Investigational Therapy For Ovarian Cancer, At SITC 40th Annual Meeting
📈 PositiveBenzinga•Oct 23, 2025, 02:12 PM
IMUNON To Host Investor R&D Day On November 10, 2025 To Present Phase 3 IMNN-001 Ovarian Cancer Study Updates
📈 PositiveBenzinga•Oct 20, 2025, 12:06 PM
Reported Earlier: Imunon To Give Oral Presentations Highlighting IMNN-101, Its Investigational DNA Plasmid Vaccine Based On The Company's Proprietary PlaCCine Technology Platform At Leading Vaccine Conferences
📈 PositiveBenzinga•Oct 17, 2025, 03:41 PM
IMUNON To Present Phase 3 OVATION 3 Clinical Trial IMNN-001 At ESMO Congress
➖ NeutralBenzinga•Oct 14, 2025, 12:21 PM
IMUNON Presents IMNN-001 Phase 2 Translational Data In Ovarian Cancer; Results Showed 13-Month Increase In Overall Survival
📈 PositiveBenzinga•Sep 22, 2025, 12:06 PM
IMUNON To Present New Translational Data From Phase 2 OVATION 2 Study Of IMNN-001 At 2025 AACR Special Conference In Cancer Research
📈 PositiveBenzinga•Sep 19, 2025, 12:07 PM
IMUNON Regains Nasdaq Compliance
📈 PositiveBenzinga•Aug 28, 2025, 12:08 PM
Frequently Asked Questions about IMNN
What is IMNN's current stock price?
Imunon, Inc. (IMNN) is currently trading at $3.75 per share. The stock has moved -1.06% today.
What is the analyst price target for IMNN?
No analyst price targets are currently available for this stock.
What sector is Imunon, Inc. in?
Imunon, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is IMNN's market cap?
Imunon, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does IMNN pay dividends?
No, Imunon, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAEON
AEON Biopharma, Inc.
$1.08
Mkt Cap: $0.0B
BOLT
Bolt Biotherapeutics, Inc.
$5.16
Mkt Cap: $0.0B
CING
Cingulate Inc.
$3.97
Mkt Cap: $0.0B
CLRB
Cellectar Biosciences, Inc.
$2.68
Mkt Cap: $0.0B
COCP
Cocrystal Pharma, Inc.
$0.99
Mkt Cap: $0.0B
DWTX
Dogwood Therapeutics, Inc.
$6.45
Mkt Cap: $0.0B
EVGN
Evogene Ltd.
$1.02
Mkt Cap: $0.0B
MRKR
Marker Therapeutics, Inc.
$1.28
Mkt Cap: $0.0B
SNSE
Sensei Biotherapeutics, Inc.
$8.86
Mkt Cap: $0.0B
TRAW
Traws Pharma, Inc.
$1.27
Mkt Cap: $0.0B
Explore stocks similar to IMNN for comparison